NCT05330455 - Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

May 19, 2025

Study Completion Date

April 3, 2026

Conditions

Hepatitis B

Interventions

DRUG

GSK3965193

GSK3965193 will be administered

DRUG

Placebo to match GSK3965193

Placebo to match GSK3965193 will be administered

DRUG

Bepirovirsen

Bepirovirsen will be administered

Trial Locations (16)

10330

GSK Investigational Site, Bangkok

20122

GSK Investigational Site, Milan

20900

GSK Investigational Site, Monza MB

35033

GSK Investigational Site, Rennes

38043

GSK Investigational Site, Grenoble

44000

GSK Investigational Site, Nantes

49241

GSK Investigational Site, Pusan

69004

GSK Investigational Site, Lyon

T2N 4Z6

GSK Investigational Site, Calgary

K1H 8L6

GSK Investigational Site, Ottawa

700-721

GSK Investigational Site, Daegu

05505

GSK Investigational Site, Seoul

CB2 2GG

GSK Investigational Site, Cambridge

SE5 9RS

GSK Investigational Site, London

SW17 0QT

GSK Investigational Site, London

W2 1NY

GSK Investigational Site, London